来源：钛媒体 在"二代"正式接班仅一年后，老牌日化代工企业嘉亨家化（300955.SZ）将迎来新的主人。 2026年1月6日，嘉亨家化的控制权变更迎来了新的进展，公司控股股东曾本生与杭州拼便宜网络科技有限公司（以下简称"拼 便宜"）和有着地方国资背景的杭州润宜企业管理咨询合伙企业（有限合伙）（以下简称"杭州润宜"）等三方签署股份转让协 议，交易最终完成后徐意将成为上市公司新的实际控制人。 上市仅五年，嘉亨家化目前已经深陷亏损泥沼，对于如何脱困对于公司实控人、已经退居二线的"终身名誉董事长"曾本生来 说，找人接盘或是最好的出路，而上市公司是否能在新股东带领下实现业绩反转还有待市场检验。 拼便宜联手浙江国资接盘 根据公告中披露的信息显示，此次控制权的变更将采用"协议转让+部分要约收购+表决权放弃"的组合交易模式。 嘉亨家化的控股股东曾本生与拼便宜、温州苍霄企业管理合伙企业（有限合伙）（以下简称"温州苍霄"）及杭州润宜企业管理 咨询合伙企业（有限合伙）（以下简称"杭州润宜"）分别签署股份转让协议。根据协议，曾本生通过协议转让方式向三方合计 出让上市公司29.70%的股份（约2989万股），其中拼便宜作为主要受让方受 ...

Core Viewpoint - The blood product giant, Palin Biotech, is set to be acquired by China National Pharmaceutical Group (Sinopharm), marking another change in ownership within two years [1][2]. Group 1: Ownership Change - On June 9, Palin Biotech announced that its controlling shareholder, Shengbang Yinghao Investment Partnership, plans to transfer 21.03% of its shares to China National Biotechnology Co., Ltd [1]. - If the transaction proceeds, the controlling shareholder will shift from Shengbang Yinghao to China National Biotechnology, with the actual controller changing from the Shaanxi Provincial State-owned Assets Supervision and Administration Commission to Sinopharm [1]. - This marks the second ownership change for Palin Biotech in less than two years, following a previous transfer of 20.99% of shares to Shengbang Yinghao in March 2023 [2]. Group 2: Financial Performance - In 2024, Palin Biotech reported a revenue of 2.655 billion yuan, a year-on-year increase of 14%, and a net profit of 745 million yuan, up 21.76%, marking seven consecutive years of profit growth [3]. - However, in Q1 2025, the company experienced a revenue decline of 14% to 375 million yuan and a net profit decrease of 26.95% to approximately 89.09 million yuan [3]. - The decline in Q1 2025 is attributed to insufficient production capacity to meet growing demand, prompting expansion efforts at its subsidiaries [3]. Group 3: Capacity Expansion - Palin Biotech is currently expanding production capacity at its subsidiaries, with the second phase of expansion at Paisfiko expected to be completed before the 2025 Spring Festival [3]. - The second phase expansion at Guangdong Shuanglin is anticipated to commence production in mid-2025, increasing annual capacity to 1,500 tons, contributing to a total capacity exceeding 3,000 tons [3]. - This expansion aims to support the company's growth and ensure sustainable long-term development [3]. Group 4: Regulatory Compliance - In May 2023, Palin Biotech faced penalties due to internal control issues leading to inaccurate information disclosure [3]. - The company submitted a rectification report on June 3, 2023, committing to enhance internal compliance management and improve information disclosure practices [4].